(Q44139126)

30 November 2017

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma (English)

1 reference

30 November 2017

13

Champlin R

1 reference

30 November 2017

1

Giralt S

1 reference

30 November 2017

5

Khouri I

1 reference

30 November 2017

Aleman A

2

1 reference

30 November 2017

Anagnostopoulos A

3

1 reference

30 November 2017

Weber D

4

1 reference

30 November 2017

Anderlini P

6

1 reference

30 November 2017

Molldrem J

7

1 reference

30 November 2017

Ueno NT

8

1 reference

30 November 2017

Donato M

9

1 reference

30 November 2017

Korbling M

10

1 reference

30 November 2017

Gajewski J

11

1 reference

30 November 2017

Alexanian R

12

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

Bone Marrow Transplantation

30 November 2017

1 reference

30 November 2017

30

1 reference

30 November 2017

6

1 reference

30 November 2017

367-373

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703652

30 November 2017

0 references

cites work

The treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

Long-term follow-up after high-dose therapy for high-risk multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

The systemic administration of intravenous melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

Metabolism and action of purine nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

Combination chemotherapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

Standard therapy versus autologous transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

Donor leukocyte infusions for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703652

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703652

1 reference

Dimensions Publication ID

30 November 2017

0 references

1 reference